echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > Just now! Chengdu leading science and technology innovation board raised 660 million yuan through IPO

    Just now! Chengdu leading science and technology innovation board raised 660 million yuan through IPO

    • Last Update: 2019-11-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Author: In the afternoon of November 22, the announcement of the results of the 48th review meeting of the Municipal Committee of science and technology innovation board in 2019 showed that the first meeting of Chengdu pilot drug development Co., Ltd (hereinafter referred to as "Chengdu pilot") was approved, and about 660 million yuan was planned to be raised for the construction of "new molecular design, construction and application platform" and "new drug research and development center" projects Chengdu was founded in 2012 by Dr Jin Li, a member of the Royal Society of chemistry, and many experts in biology and chemistry at home and abroad Since its establishment, the company has been focusing on DNA encoded compound library (abbreviated as DNA encoded Compound Library) Del) technology focuses on research and creation, focusing on the early stage research and development of original new drugs - the discovery of seedling compounds and lead compounds The company is located in Tianfu international biological city, Chengdu, Sichuan Province, with a R & D base of nearly 20000 square meters The core technology, DNA coding compound library (DEL), can produce a large number of new small molecular compounds quickly, efficiently and cheaply Relying on its leading del technology and related supporting drug design, screening and optimization platform, Chengdu leader can provide technical services for partners in the early stage of drug discovery and compound synthesis By the end of the reporting period, the company has built a small DNA coding compound library with all independent intellectual property rights and more than 400 billion molecular structures - the pilot library Specific businesses include: del screening service, del library customization service, chemical synthesis service, new drug R & D project transfer, etc Jin Li is the leading controlling shareholder and actual controller in Chengdu As of the date of signing the prospectus, Jin Li (Li Jin) directly holds 22.74% of the voting rights of Chengdu leader, and indirectly controls 10.74% of the voting rights of Chengdu leader through Juzhi technology innovation, and controls 33.48% of the voting rights of Chengdu leader in total At present, the core revenue of the company mainly comes from the two revenue of del screening and del library customization During the reporting period, the company's overall revenue increased significantly, from 2016 to 2018, it was 16.4291 million yuan, 53.2187 million yuan and 151.196 million yuan respectively, and the growth rates in 2017 and 2018 were 223.93% and 184.10% respectively compared with the previous year From the regional distribution of the company's revenue over the years, from 2016 to the first quarter of 2019, the operating revenue from the United States accounted for 80.8%, 84.85%, 84.14% and 80.24% of the total revenue respectively It can be seen that the company depends on the sales of a single region In addition, the company's net profit during the reporting period mainly depends on the risk of government subsidies In the first half of 2019, the company generated a net profit of 59.6725 million, while the subsidy received in the same period was 43.4771 million In 2016, 2017, 2018 and the first half of 2019, the government subsidies included in the profit and loss of the company were 7.7810 million yuan, 10.1227 million yuan, 19.3046 million yuan and 43.4771 million yuan respectively The proportion of government subsidies included in the profit and loss of the company in 2018 and the first half of 2019 accounted for 42.94% and 72.86% of the current net profit respectively About 660 million yuan of the total investment of the project is planned to be used for "new molecular design, construction and application platform" and "new drug R & D center" fund-raising projects.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.